share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股東委託書決議
美股SEC公告 ·  2024/09/28 05:24

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals, Inc. (Adial) has announced the upcoming 2024 Annual Meeting of Stockholders to be held on November 12, 2024. The meeting will address several key proposals, including the election of two Class III directors, the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the number of shares available under the 2017 Equity Incentive Plan from 500,000 to 2,000,000. Additionally, advisory votes will be held on executive compensation and the frequency of future advisory votes on executive compensation. The Board of Directors has fixed September 26, 2024, as the record date for determining stockholders entitled to notice and vote at the meeting. Proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2023, will be mailed to stockholders around October 3, 2024. The Board recommends voting for all the proposals and has provided detailed information regarding the meeting's agenda, executive compensation, and related-party transactions.
Adial Pharmaceuticals, Inc. (Adial) has announced the upcoming 2024 Annual Meeting of Stockholders to be held on November 12, 2024. The meeting will address several key proposals, including the election of two Class III directors, the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the number of shares available under the 2017 Equity Incentive Plan from 500,000 to 2,000,000. Additionally, advisory votes will be held on executive compensation and the frequency of future advisory votes on executive compensation. The Board of Directors has fixed September 26, 2024, as the record date for determining stockholders entitled to notice and vote at the meeting. Proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2023, will be mailed to stockholders around October 3, 2024. The Board recommends voting for all the proposals and has provided detailed information regarding the meeting's agenda, executive compensation, and related-party transactions.
Adial Pharmaceuticals, Inc.（Adial）宣佈將於2024年11月12日舉行股東年會。 會議將討論幾項關鍵提案，包括選舉兩名三等董事，將Marcum LLP定爲截至2024年12月31日財政年度的獨立註冊會計師事務所，並批准修改2017年股權激勵計劃股票數量從50萬股增加到200萬股的提案。此外，還將就執行薪酬及未來執行薪酬諮詢投票頻率進行表決。 董事會已確定2024年9月26日爲確定有權收到會議通知和投票的股東記錄日。 代理材料，包括截至2023年12月31日的10-k年度報告，將於2024年10月3日左右寄給股東。 董事會建議投票支持所有提案，並提供了關於會議議程、執行薪酬和關聯交易的詳細信息。
Adial Pharmaceuticals, Inc.（Adial）宣佈將於2024年11月12日舉行股東年會。 會議將討論幾項關鍵提案，包括選舉兩名三等董事，將Marcum LLP定爲截至2024年12月31日財政年度的獨立註冊會計師事務所，並批准修改2017年股權激勵計劃股票數量從50萬股增加到200萬股的提案。此外，還將就執行薪酬及未來執行薪酬諮詢投票頻率進行表決。 董事會已確定2024年9月26日爲確定有權收到會議通知和投票的股東記錄日。 代理材料，包括截至2023年12月31日的10-k年度報告，將於2024年10月3日左右寄給股東。 董事會建議投票支持所有提案，並提供了關於會議議程、執行薪酬和關聯交易的詳細信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Organovo Holdings
    ONVO
    -- 1.270
    Silexion Therapeutics
    SLXN
    -- 1.230
    LAVA Therapeutics
    LVTX
    -- 1.340
    Dominari Holdings
    DOMH
    -- 9.900
    GT Biopharma
    GTBP
    -- 2.4600
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股集體大漲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 $阿里巴巴 (BABA.US)$ 第三財季總營收同比增長8%，AI助推阿裏雲收入大漲13%。 🎙️討論： 1. 阿裏巴巴Q3單季報發布後股價飆升。此時是否是入場良 展开
    中國股票的瘋狂反彈暫停了？華爾街仍然對熱門股下注